Impact of hospital-administered extended-release naltrexone on readmission rates for patients with alcohol use disorder
- PMID: 38984396
- DOI: 10.1111/imj.16467
Impact of hospital-administered extended-release naltrexone on readmission rates for patients with alcohol use disorder
Abstract
Background and aims: Alcohol use disorder (AUD) is a persistent public health concern, contributing significantly to mortality and morbidity. This study aims to evaluate the impact of in-hospital extended-release naltrexone (XR-NTX) administration on alcohol-related outcomes.
Methods: This retrospective cohort study, conducted at an academic medical centre, included 141 adult patients with AUD who received XR-NTX between December 2020 and June 2021. Primary and secondary outcomes were assessed 90 days before and after XR-NTX administration to identify number of alcohol-related hospitalisations, emergency department (ED) visits and average length of hospital stay. Subgroup analyses assessed outcomes in high hospital utilisers and marginally housed or unhoused populations.
Results: There was a significant decrease in ED visits and length of hospital stay post XR-NTX and no significant difference in the number of rehospitalisations. Subgroup analysis showed significant reduction in hospital readmissions and ED visits among high hospital utilisers. Our sample was a predominantly middle-aged, male and white patient population.
Conclusions: In-hospital initiation of XR-NTX for AUD was associated with a significant decrease in ED visits and length of hospital stay. While no significant impact on the number of hospitalisations was observed overall, there was a substantial reduction in hospital readmissions and ED visits among high utilisers. Our findings suggest the potential benefits of in-hospital XR-NTX, emphasising the need for further research to establish causal relationships, assess cost-effectiveness and explore effectiveness across diverse patient populations. Effective in-hospital interventions, such as XR-NTX, hold promise for improving patient outcomes and reducing the healthcare burden associated with AUD.
Keywords: alcohol use disorder; hospital readmission; naltrexone; treatment.
© 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
References
-
- American Psychiatric Association (Ed.). Diagnostic and Statistical Manual of Mental Disorders: DSM‐5‐TR (Fifth edition, text revision). American Psychiatric Association Publishing; 2022.
-
- CDC. Alcohol and Public Health: Alcohol‐Related Disease Impact [Table]. Annual Average for United States 2015–2019 Alcohol‐Attributable Deaths Due to Excessive Alcohol Use, All Ages. Available from URL: https://nccd.cdc.gov/DPH_ARDI/default/default.aspx.
-
- Substance Abuse and Mental Health Services Administration. (2021). Key Substance Use and Mental Health Indicators in the United States: Results from the 2020 National Survey on Drug Use and Health (HHS Publication No. PEP21‐07‐01‐003, NSDUH Series H‐56). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. Retrieved from URL: https://www.samhsa.gov/data/sites/default/files/reports/rpt35325/NSDUHFF....
-
- Englander H, Dobbertin K, Lind BK, Nicolaidis C, Graven P, Dorfman C et al. Inpatient addiction medicine consultation and post‐hospital substance use disorder treatment engagement: a propensity‐matched analysis. J Gen Intern Med 2019; 34: 2796–2803.
-
- Martin M, Clement J, Defries T, Makam AN, Nguyen OK. Prevalence and characteristics of hospitalizations with unhealthy alcohol use in a safety‐net hospital from 2016 to 2018. J Gen Intern Med 2022; 37: 3211–3213.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
